-
Most Recent
Cannabis Stocks
Cannabis is a psychoactive drug that is a part of the Cannabacaee plant family. In the past few years, acceptance of the drug has risen dramatically. Industry leaders, like Canopy Growth and Curaleaf, are quickly establishing the framework for legal cannabis sales. THC is believed to be the component in cannabis that creates the psychoactive effect, which can be used to treat depression, anxiety, sleeping problems, and a wide range of other issues.
3 Cannabis Stocks That Can Be Massive Wealth Creators by 2030
These are the cannabis stocks to buy as they represent companies with improving fundamentals and accelerated growth outlook.
7 Growth Stocks That Could 7X in the Next 7 Years
Investors consider these growth stocks to buy since they represent companies with good fundamentals and a positive industry outlook.
3 Cannabis Stocks to Sell in August Before They Crash & Burn
Marijuana could be a major industry in the U.S. if it was legalized but these cannabis stocks to sell have other problems to contend with.
Other industries you might be interested in
Recent Cannabis Stocks Articles
Where Is the Rebound for Fallen Canopy Growth Stock?
What are investors worried about ahead of the upcoming CGC earnings report? For many, it's the expectation of near-term losses.
Stay Far Away From Canopy Growth Stock … For Now
Taking the plunge in CGC today could prove a massive mistake, but that’s not to say buying Canopy Growth stock won’t make a worthy investment in the longer term.
Cronos Australia Offers Little Help to Cronos Group Stock
Cronos Australia could help lend some credibility to Cronos Group, but it appears too small to significantly affect CRON stock.
Wait for the Dust to Settle Before Buying Canopy Growth Stock
CGC stock has fallen 50% since July. But with the pot stock maelstrom just starting, wait for lower prices to buy Canopy Growth stock.
Plunging Tilray Stock Shows Just How Much Sentiment Has Changed
Tilray stock keeps falling and now is nearing its IPO price. Trading in TLRY stock shows how much faith investors have lost in pot stocks.
This $2 Billion Cannabis Catalyst Is Just Days Away
Cannabis companies are on the verge of ushering in a whole new category of products and welcoming a brand-new group of consumers.
HEXO Stock Has Crashed — And It May Drop Even More
Hexo stock suffered after it withdrew its outlook ahead of its Q4 earnings report. Investors worry this may not be the end.
Canopy Growth Stock Has Gone Up in Smoke
The cannabis stock frenzy has ended and now realism has set in. Now the CGC bulls must earn the market's trust once again.
Aleafia’s Announcement Should Concern Aphria Stock Investors
The lack of clarity regarding the Aleafia agreement is yet another reason Aphria stock holders should be concerned.
Avoid Cronos Group Stock Even After Yesterday’s Cannabis Carnage
Health impact of vaping makes CRON stock a concern from a regulatory and growth perspective. Keep it on the investment radar, but shares aren't likely to trend higher anytime soon.
Is Aurora Cannabis’ Growth Strategy Enough to Turn Around ACB Stock?
Global operations and distribution are a large part of Aurora's strategy. Will it be enough to turn around the decline of ACB stock?
Here’s How the Mandela Effect Has Hurt Cronos Group Stock
Hysteria over the vaping crisis has hurt CRON stock. But investors should have patience until all the facts are straightened out.
Aurora Cannabis Stock Is Down, But Not Dead
As cannabis stocks have come back down to Earth, darlings like ACB stock have taken a hit. But the future for Aurora Cannabis looks bright.
Square (SQ Stock) Disrupts Yet Another Industry
Square is a dream come true for small business owners. And, as of Thursday, that’s now true for a whole new (and red-hot) market: cannabidiol (CBD).
Investors Should Wait to Buy Canopy Growth Stock Until Profits Appear
Canopy Growth stock continues to falter. Its operating losses and acquisitions continue to bleed its value. Wait for profits to show up.
Hold Your Nose and Buy Canopy Growth Stock
CGC stock has continued to slide since a Bank of America downgrade in late September. But even the analyst that downgraded the stock admits the long-term outlook for Canopy is bullish.
